← Back to Search

Other

PF-07220060 Tablet Forms in Healthy Adults

Phase 1
Recruiting
Research Sponsored by Pfizer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
BMI of 17.5-30.5 kg/m2; and a total body weight >50 kg (110 lb)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours pf-07220060 post-dose
Awards & highlights

Study Summary

This trial compares two formulations of a medicine (PF-07220060) and how they are absorbed into the bloodstream. It also looks at the effects of food & Rabeprazole medicine on the uptake of the medicine.

Who is the study for?
Healthy adults aged 18-65 with a BMI of 17.5-30.5 kg/m2 and weight over 50 kg can join this study. They must be in good health as confirmed by medical exams, tests, and have no history of conditions affecting drug absorption or serious diseases like HIV or hepatitis.Check my eligibility
What is being tested?
The trial is testing two different tablet forms of PF-07220060 to see how they are absorbed into the bloodstream, with and without food, and under the influence of Rabeprazole (a proton pump inhibitor).See study design
What are the potential side effects?
Potential side effects aren't specified but may include reactions typical for clinical trials such as nausea, headache, digestive issues or allergic reactions depending on individual tolerance to PF-07220060.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My BMI is between 17.5 and 30.5, and I weigh more than 110 lbs.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours pf-07220060 post-dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and 0 (pre-dose), 0.5, 0.75, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, and 72 hours pf-07220060 post-dose for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time(AUCinf) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations
Maximum Observed Plasma Concentration (Cmax) of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations
Secondary outcome measures
AUCinf of PF-07220060 to estimate relative bioavailability of PF-07220060 two tablet formulations at a second dose level
AUCinf of PF-07220060 to estimate the effect of a PPI (rabeprazole) on the bioavailability of a PF-07220060 tablet formulation under fasted condition
AUCinf of PF-07220060 to estimate the effect of a PPI (rabeprazole) on the bioavailability of a PF-07220060 tablet formulation under fed condition
+9 more

Trial Design

7Treatment groups
Experimental Treatment
Group I: Treatment G (Cohort 7)Experimental Treatment1 Intervention
Participants will receive PF-07220060 and Rabeprazole tablet by mouth
Group II: Treatment F (Cohort 6)Experimental Treatment1 Intervention
Participants will receive PF-07220060 and Rabeprazole tablets by mouth
Group III: Treatment E (Cohort 5)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Group IV: Treatment D (Cohort 4)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Group V: Treatment C (Cohort 3)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Group VI: Treatment B (Cohort 2)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth
Group VII: Treatment A (Cohort 1)Experimental Treatment1 Intervention
Participants will receive PF-07220060 tablet by mouth

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

PfizerLead Sponsor
4,563 Previous Clinical Trials
10,907,010 Total Patients Enrolled
Pfizer CT.gov Call CenterStudy DirectorPfizer
3,471 Previous Clinical Trials
8,088,283 Total Patients Enrolled

Media Library

PF-07220060 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05923411 — Phase 1
Healthy Subjects Research Study Groups: Treatment A (Cohort 1), Treatment B (Cohort 2), Treatment C (Cohort 3), Treatment D (Cohort 4), Treatment E (Cohort 5), Treatment F (Cohort 6), Treatment G (Cohort 7)
Healthy Subjects Clinical Trial 2023: PF-07220060 Highlights & Side Effects. Trial Name: NCT05923411 — Phase 1
PF-07220060 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05923411 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What health risks may be associated with Treatment A (Cohort 1) for patients?

"The clinical data available on Treatment A (Cohort 1) is scarce, resulting in a safety ranking of 1. This assessment was conducted by Power's medical team as this study only constitutes a Phase 1 trial."

Answered by AI

Is this clinical research still open to enrollees?

"Clinicaltrials.gov records indicate that recruitment for this medical trial has ended, with the study being first posted on July 11th 2023 and last edited two weeks later. Despite its inactive status, there are currently 793 other trials actively searching for volunteers."

Answered by AI

Is participation in this research limited to adults under the age of 25?

"This clinical research necessitates participants have ages between 18 and 65. There are 55 trials specifically for minors and 368 studies directed at individuals aged over 65 years old."

Answered by AI

Who qualifies to join this research project?

"This trial is recruiting 84 participants in the 18 to 65 age bracket who are deemed medically fit, as established through physical examination and laboratory tests. Furthermore, these individuals must have a BMI of 17.5-30.5 kg/m2; body weight >50 kg (110 lb) and sign an Informed Consent Document (ICD)."

Answered by AI

Who else is applying?

What site did they apply to?
New Haven Clinical Research Unit
What portion of applicants met pre-screening criteria?
Met criteria

Why did patients apply to this trial?

I am a healthy 60 year old person.
PatientReceived 2+ prior treatments
~48 spots leftby Apr 2025